Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...
Citi keeps a Neutral rating on Pfizer (PFE) with a $30 price target following a transfer of coverage. The shares have underperformed over past ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...
This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback